Skip to content

19-041 - Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer Participants

Status: open

LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Treatment for Lung Cancer

Contact Us


This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.


This trial is sponsored by SWOG.

Providers Associated With This Trial

Principle Investigator

  • Persing brianView Profile
    Brian E. Persing, M.D.Medical Oncologist and HematologistDivision Director, Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology; Program Director, Medical Oncology Fellowship; Assistant Professor of Medical Oncology

Sub Investigators

    This link will open in a new tab or window.